PT 20

Drug Profile

PT 20

Alternative Names: Modified ferric oxide adipate - Shield therapeutics; PT-20

Latest Information Update: 27 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medical Research Council
  • Developer Medical Research Council; Phosphate Therapeutics
  • Class Ferric compounds; Hyperphosphataemia therapies; Small molecules
  • Mechanism of Action Phosphate binding modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Hyperphosphataemia

Most Recent Events

  • 27 Sep 2016 Phase-II development is ongoing in USA
  • 20 Sep 2016 PT 20 will be available for licensing as from 01 Jan 2017. http://www.shieldtherapeutics.com/investors/
  • 07 May 2015 Adverse events data from a phase IIb trial in Hyperphosphataemia released by Phosphate Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top